Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 15/20 | 0.42 |
| ▸ | WNT1 | P04628 | 14/20 | 0.42 |
| ▸ | GSK3B | P49841 | 14/20 | 0.42 |
| ▸ | BRAF | P15056 | 1/20 | 0.39 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.38 |
| ▸ | KARS1 | Q15046 | 1/20 | 0.37 |
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.37 |
| ▸ | CLK2 | P49760 | 1/20 | 0.36 |
| ▸ | CLK3 | P49761 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16776301 | 0.91 | GSK3B (0.39) | DYRK1AWNT1GSK3BBRAFIMPDH2 | |
| SCHEMBL17618330 | 0.90 | IMPDH2 (0.45) | BRAFIMPDH2BRD4CREBBP | |
| SCHEMBL16775780 | 0.89 | IMPDH2 (0.37) | DYRK1AWNT1GSK3BBRAFIMPDH2 | |
| SCHEMBL17624498 | 0.89 | RHOA (0.40) | DYRK1AWNT1GSK3BBRAFKARS1 | |
| SCHEMBL19706100 | 0.89 | DYRK1A (0.39) | DYRK1AWNT1GSK3BBRAFBRD4 | |
| SCHEMBL17618869 | 0.87 | DYRK1A (0.42) | DYRK1AWNT1GSK3BCLK2CLK3 | |
| SCHEMBL17767959 | 0.87 | DYRK1A (0.42) | DYRK1AWNT1GSK3BCLK2CLK3 | |
| SCHEMBL19699109 | 0.87 | DYRK1A (0.39) | DYRK1AWNT1GSK3BBRAFCLK2 | |
| SCHEMBL16776266 | 0.86 | GAA (0.42) | DYRK1AGSK3BKARS1CA9 | |
| SCHEMBL17618856 | 0.86 | DYRK1A (0.39) | DYRK1AWNT1GSK3BBRAFCLK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170355697-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2017-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355697-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | DYRK1A 2623/4885WNT1 3363/4885GSK3B 1728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.